[ad_1]
In the laboratory of the Santara Clinics of the Vilnius University Hospital, 15 purposely selected samples were examined (based on the absence of the S gene from the PCR product); 13 cases were classified as “British”.
In the laboratory of the Kaunas Clinics of the Lithuanian University of Health Sciences, of the 85 samples tested, 11 were also found to have a “British” mutation.
The laboratory of the European Center for Disease Prevention and Control, which assists Lithuania in sequencing studies, examined 159 of the 188 samples submitted and 1 detected the virus line B.1.1.7.
According to DSP Baksha, Director of NVSPL, samples for sequencing studies are selected from various regions of Lithuania in order to assess the prevalence of mutations both throughout the country and in their individual regions. Some of the samples are randomly selected and others according to specific selection criteria, such as the Santara clinics, to examine 15 cases, most of which were confirmed as cases of the B.1.1.7 virus line.
According to NSPL data, a total of 37 cases of the B.1.1.7 virus line have been detected in Lithuania since February.
If you have any questions about the COVID-19 vaccine, please send them to our editorial staff by email. Email address [email protected]
[ad_2]
